Pneumonia Vaccines Market Gains Momentum with Adult Immunization Push

Pneumonia Vaccines Market Size to Hit USD 15.46 Billion by 2030 as MSD Korea Launches Adult-Focused 21-Valent Vaccine

The global Pneumonia Vaccines Market is entering a new growth phase after MSD Korea officially launched Capvaxive, a 21-valent pneumococcal conjugate vaccine tailored for adults, while researchers at BITS Pilani Hyderabad Campus announced the development of an experimental AI-assisted multiepitope pneumonia vaccine candidate targeting multiple bacterial strains. The developments are reshaping competitive dynamics across respiratory immunization markets, with industry estimates projecting the global pneumonia vaccines market to reach USD 15.46 billion by 2030, growing at a CAGR of 6.52%.

The latest announcements reflect a broader industry shift toward next-generation pneumococcal vaccines designed to address emerging serotypes, aging populations, and limitations associated with conventional polysaccharide and conjugate vaccine platforms. Analysts note that governments and vaccine manufacturers are increasingly prioritizing adult immunization programs amid rising pneumonia-related mortality and antimicrobial resistance concerns globally.

MSD Korea Expands Adult Pneumococcal Vaccine Portfolio

MSD Korea’s March 2026 launch of Capvaxive marks one of the most significant recent advancements in adult pneumococcal immunization in Asia. The newly introduced 21-valent pneumococcal conjugate vaccine was approved by South Korea’s Ministry of Food and Drug Safety in August 2025 and is designed to prevent invasive pneumococcal disease (IPD) and pneumonia among adults aged 18 and older.

According to company disclosures, the vaccine includes eight unique serotypes not covered by earlier pneumococcal vaccines and specifically targets strains responsible for nearly 80% of adult IPD cases in the United States between 2018 and 2022. Clinical findings from the global STRIDE Phase 3 trials reportedly demonstrated superior immunogenicity across multiple non-shared serotypes compared with existing comparator vaccines.

The launch also highlights growing concern surrounding adult pneumonia cases in aging populations. In South Korea, pneumonia ranked among the leading causes of death in 2024, intensifying demand for broader-spectrum respiratory vaccines.

“Adult immunization is becoming one of the fastest-evolving segments within the respiratory vaccine ecosystem,” said Jayanta Das, Research Analyst at Next Move Strategy Consulting. “Manufacturers are increasingly focusing on higher-valency formulations and broader serotype coverage as epidemiological patterns shift beyond traditional pediatric populations.”

BITS Hyderabad Researchers Advance AI-Based Experimental Vaccine

Separately, researchers at BITS Pilani Hyderabad reported the development of an experimental synthetic multiepitope vaccine targeting Streptococcus pneumoniae, the bacterium responsible for pneumonia, meningitis, and sepsis.

The research team, led by Kirtimaan Syal, used immunoinformatics, bioinformatics, and artificial intelligence tools to identify highly immunogenic bacterial protein fragments capable of triggering broader immune responses across multiple pneumococcal strains.

Unlike conventional pneumococcal vaccines that rely on bacterial capsules, the experimental platform focuses on selected epitopes from outer cell wall proteins including Ply, PspA, and PsaA. Researchers believe the strategy may help address limitations posed by more than 100 known pneumococcal serotypes, many of which remain outside current vaccine coverage.

According to NMSC proprietary analysis, AI-assisted vaccine discovery platforms have witnessed a notable increase in R&D investments over the last six months, particularly in infectious disease prevention and precision immunology.

Rising Adult Immunization Demand Reshapes Market Dynamics

Healthcare systems worldwide are expanding adult vaccination strategies due to increasing rates of invasive pneumococcal disease among elderly and immunocompromised populations. Industry experts also point to rising antibiotic resistance as a major catalyst supporting preventive vaccine adoption.

Recent regulatory approvals and academic breakthroughs have intensified competition among pharmaceutical companies developing broader-spectrum pneumococcal vaccines capable of improving long-term immunity and reducing strain replacement risks.

Regional Market Outlook

NMSC researchers identified Asia-Pacific as one of the fastest-growing regions for pneumonia vaccine adoption due to expanding healthcare access, stronger immunization awareness campaigns, and rising respiratory disease burden across densely populated economies.

Competitive Landscape Intensifies

Major pharmaceutical companies are accelerating investments in next-generation respiratory vaccines as governments strengthen disease prevention programs.

Key industry participants include:

• Pfizer 

• Merck & Co. 

• GlaxoSmithKline 

• Sanofi 

• Serum Institute of India 

Industry analysts expect competitive differentiation to increasingly focus on broader serotype coverage, AI-driven antigen discovery, scalable manufacturing, and adult-focused immunization programs through the remainder of the decade.

What CEOs and Investors Should Do Next

• Expand investment in adult pneumococcal vaccine portfolios and higher-valency technologies. 

• Explore AI-driven vaccine discovery collaborations with academic research institutions. 

• Strengthen manufacturing capabilities for scalable respiratory vaccine production. 

• Monitor regulatory pathways for next-generation conjugate vaccines in Asia-Pacific markets. 

• Prioritize emerging-market partnerships focused on affordable vaccine accessibility. 

The latest vaccine developments from South Korea and India underscore how the pneumonia prevention landscape is rapidly evolving toward precision immunology, broader strain coverage, and AI-assisted vaccine innovation. Analysts expect continued investment momentum as healthcare systems intensify focus on adult respiratory disease prevention through 2030.

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes NMSC different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more information, please contact:

Next Move Strategy Consulting

5th Floor 867

Boylston St, STE 500,

Boston, MA 02116, U.S.

E-Mail: [email protected]

Direct: +1-217-650-7991

Website: www.nextmsc.com